Overexpression of SRC-3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness

Fang-Ping Xu\textsuperscript{1}, Yan-Hui Liu\textsuperscript{1}, Xin-Lan Luo\textsuperscript{1}, Fen Zhang\textsuperscript{1}, Hai-Yu Zhou\textsuperscript{2}, Yan Ge\textsuperscript{1}, Chao Liu\textsuperscript{1}, Jie Chen\textsuperscript{1}, Dong-Lan Luo\textsuperscript{1}, Li-Xu Yan\textsuperscript{1}, Ping Mei\textsuperscript{1}, Jie Xu\textsuperscript{1} & Heng-Guo Zhuang\textsuperscript{1}

\textsuperscript{1}Department of Pathology and Laboratory Medicine, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
\textsuperscript{2}Department of Thoracic Surgery, Cancer Center, Guangdong General Hospital, Guangzhou, China

Keywords
Cell growth, cell invasion, esophageal squamous cell carcinoma, insulin-like growth factor/AKT, steroid receptor coactivator-3

Abstract
Steroid receptor coactivator-3 (SRC-3), a transcriptional coactivator for nuclear receptors and other transcription factors, plays an important role in the genesis and progression of several cancers. However, studies investigated the role of SRC-3 in esophageal squamous cell carcinomas (ESCCs) are limited, and the role of SRC-3 in tumor progression remains unclear. We examined the expression of SRC-3 in 8 ESCC cell lines and 302 human ESCC tissues by qPCR, Western blot, and immunohistochemistry. In addition, ESCC cell lines were subjected to proliferation and invasion assays, tumorigenicity assay, flow cytometry assay, qPCR, Western blot, and Chromatin Immunoprecipitation assay to investigate the role of SRC-3 in cancer progression. SRC-3 was overexpressed in 48% of cases and correlated with poor overall (\(P = 0.0076\)) and progression-free (\(P = 0.0069\)) survival of surgically resected ESCC patient. Cox regression analysis revealed that SRC-3 is an independent prognostic marker. Furthermore, we found that activation of insulin-like growth factor (IGF)/AKT) was involved in the SRC-3 on the cell growth and invasiveness in two ESCC cell lines, Eca109 and EC18 cells. SRC-3 overexpression is clinically and functionally relevant to the progression of human ESCC, and might be a useful molecular target for ESCC prognosis and treatment.

Introduction
Esophageal cancer is the sixth most common cause of death and eighth most common cancer in the world [1]. Esophageal squamous cell carcinoma (ESCC) accounts for more than 90% of the esophageal cancer cases and is predominant in East Asian countries, especially in China [2]. Despite the development of multimodality therapies, the prognosis of patients remains poor, even for those who undergo complete resection of their carcinomas [3, 4]. Therefore, there is a great need to discover more biomarkers and therapeutic targets for ESCC patients. Steroid receptor coactivator-3 (SRC-3; AIB1/ACTR/ RAC3/p/CIP/NCoA-3) is a member of the p160 SRC family. SRC-3 has histone acetyltransferase activity and interacts with multiple nuclear receptors and transcription factors to regulate the expression of their target genes, which has been reported to be involved in a number of biological processes, such as cell proliferation, differentiation, migration, and others [5, 6]. SRC-3 is well studied in breast cancer and prostate cancer. Overexpression of SRC-3 has been demonstrated to associate with poor disease-free survival and play an important role in the genesis and progression of some breast cancers and prostate cancers [7, 8]. Elevated SRC-3 gene and protein
expression are also found in many other hormone-independent cancers, including human gastric, pancreatic, bladder, liver, and lung cancers, and correlated with cancer cell proliferation, invasiveness, and poor prognosis of the tumor [9–14]. Knockdown of SRC-3 in lung cancers not only reduces cell growth and proliferation of non–small cell lung cancer cell lines but also potentiates the effects of gefitinib in EGFR tyrosine kinase inhibitor-resistant cells [14]. Those studies indicate that SRC-3 plays an oncogenic role in carcinomas. Our previous study indicated that SRC-3 was amplified and overexpressed in a subset of ESCCs, suggesting a potential impact of SRC-3 on ESCC [15]. However, studies investigating the role of SRC-3 in ESCC are limited, and the knowledge of the function of SRC-3 in ESCC cell growth and invasiveness is also to be revealed.

Herein, we show that overexpression of SRC-3 correlated with poor progression-free and overall survival of surgically resected ESCC patient. Downregulation of SRC-3 decreased the aggressive phenotype of ESCC cells both in vitro and vivo. Furthermore, our studies supported that the oncogenic effects of SRC-3 might be through enhancing insulin-like growth factor (IGF)/AKT pathway.

**Materials and Methods**

**Case selection and tissue microarray construction**

In this study, the paraffin-embedded pathological specimens from 315 patients with ESCC were obtained from the Guangdong General Hospital (Guangzhou, China) between July 2004 and July 2009. None of the patients received neoadjuvant therapy before surgery. Clinicopathologic characteristics were detailed in Table 1. The tissue microarray (TMA) was constructed according to a method described previously [15]. Briefly, H&E stained slides from each tumor block were used as guide to identify areas representing different stages of progression from each case, which were sampled using a tissue arraying instrument (Beecher Instruments, Silver Spring, MD) to remove a 0.6-mm-diameter cylinder of tissue. Then, the cylinder was reembedded into a predetermined position in a recipient paraffin block. In this ESCC TMA, two cores of sample were selected from each tumor and one core from adjacent nonneoplastic esophageal mucosa of the same patients. Tumor grade and stage were defined according to the criteria of the WHO (2010) and the 7th edition of the TNM classification of the AJCC (2010). The Institute Research Medical Committee of Guangdong General Hospital gave approval for this study.

**Immunohistochemistry (IHC)**

See Appendix S1.

| Characteristic          | Cases | Overexpression (%) | P value$^1$ |
|-------------------------|-------|--------------------|-------------|
| Age                     |       |                    |             |
| ≤58 yrs                 | 160   | 81 (50.6%)         | 0.277       |
| >58 yrs                 | 142   | 63 (44.4%)         |             |
| Gender                  |       |                    |             |
| Male                    | 229   | 111 (48.5%)        | 0.627       |
| Female                  | 73    | 33 (45.2%)         |             |
| Histologic differentiation|     |                    |             |
| Well                    | 47    | 25 (53.2%)         | 0.200       |
| Moderate                | 201   | 99 (49.3%)         |             |
| Poor                    | 54    | 20 (37.0%)         |             |
| T Classification        |       |                    |             |
| T1-2                    | 115   | 45 (39.1%)         | 0.020       |
| T3-4                    | 187   | 99 (52.9%)         |             |
| N classification        |       |                    |             |
| N0                      | 150   | 70 (46.7%)         | 0.726       |
| N1-3                    | 152   | 74 (48.7%)         |             |
| M classification        |       |                    |             |
| M0                      | 296   | 141 (47.6%)        | 0.909       |
| M1                      | 6     | 3 (47.7%)          |             |
| Clinical stage          |       |                    |             |
| I–II                    | 172   | 74 (43.0%)         | 0.062       |
| III–IV                  | 130   | 70 (53.8%)         |             |

$^1$Chi-Square test. Bold value here highlight the significant value ($P <0.05$)

**Cell culture**

Eight human ESCC cell lines, including CaES-17, EC18 (gift from Professor Guan), Eca109, EC9706, KYSE-140, KYSE-450,KYSE-510, and TE-1, one immortalized human normal esophageal epithelial cell (HEEC), and one human embryonic kidney 293 (HEK293) cell lines purchased commercially were maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, San Diego, CA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT) and 1% penicillin/streptomycin in a humidified atmosphere with 5% CO₂. All of the cell lines have been DNA fingerprinted for provenance using the Goldeneye™20A STR Multiplex Kit. The DNA fingerprint was all confirmed to the same as in the DNA fingerprint library maintained by ATCC, DSMZ, JCRB, or the primary source of the lines. The lines were also tested to be free of mycoplasma contamination.

**Vectors, retroviral infection, and stable cell line selection**

See Appendix S1.

**RNA extraction, cDNA synthesis, and qPCR**

See Appendix S1.
Western blot analysis
5-bromo-2′-deoxyuridine (BrdU) incorporation assays and Methyl thiazolyl tetrazolium (MTT) assays
See Appendix S1.

Colony formation and soft agar assays
See Appendix S1.

Flow cytometry assay
See Appendix S1.

Wound healing assay and transwell assay
See Appendix S1.

Chromatin immunoprecipitation (ChIP) assay
See Appendix S1.

Tumorigenicity assay
The study protocol was approved by and performed in accordance with the guidelines of the laboratory animal ethics committee of Guangdong General Hospital. For SRC-3 transplantation studies, retroviral-delivered shRNA SRC-3 and shRNA scramble control cells were injected subcutaneously into the flank of 4-week-old male athymic nude mice (five mice per group; BiKai Co., Shanghai, China) in complete medium. Tumor diameters were measured with digital calipers, and the tumor volume was calculated in cubic millimeters. Animals were followed for 32 days, and all animals were sacrificed and the tumor weights were measured at the conclusion of the experiment.

Statistical analysis
Statistical tests for data analysis included Fisher exact test or Chi-square test, log-rank test, and Student two-tailed t-test. Survival curves were assessed by the Kaplan–Meier method and compared by the log-rank test. Relative risks of cancer-related death associated with SRC-3 expression status and other predictor variables were estimated by univariate analyses. Multivariate survival analysis was done on all parameters that were found to be significant on univariate level using the Cox regression model. Covariates including patient’s age, gender, tumor grade, SRC-3 expression, TNM, and clinical stage were used to adjust for in the Cox proportional hazard model. Statistical analyses were performed using the SPSS 13.0 statistical software package (SPSS Inc, Chicago, IL). A P value of less than .05 was considered significant.

Results
SRC-3 overexpression correlates with progression and poor prognosis in human ESCC
To investigate the oncogenic role of SRC-3 in ESCC progression, we first examined the expression of SRC-3 in ESCC cell lines and human ESCC tissues. As shown in Figure 1A and B, SRC-3 was upregulated at both the protein and messenger RNA (mRNA) levels in all eight analyzed ESCC cell lines compared to one primary HEEC and one HEK293 cells. The expression level of SRC-3 was examined in 315 paraffin-embedded, archived ESCC tissues using IHC. Informative expression of SRC-3 was detected in 302 ESCC cases. SRC-3 was markedly upregulated in ESCC but was only detectable at low levels in normal esophageal tissues (Fig. 1C). The results of the IHC analysis are summarized in Table 1. Overexpression of SRC-3 was detected in 144 of 302 (47.7%) of informative ESCC cases. Statistical analyses revealed that SRC-3 expression was significantly associated with advanced tumor stage ($P = 0.020$) and tended to be more frequent in clinical stage III–IV ($P = 0.062$) patients with ESCC. Therefore, upregulation of SRC-3 in ESCC specimens as well as ESCC cell lines suggests that SRC-3 may be involved in ESCC progression.

Moreover, Kaplan–Meier analysis was performed on the 242 patients subset for which survival data were available. As shown in Figure 1D, patients whose tumors have high SRC-3 levels by immunohistochemistry have significantly shorter overall ($P = 0.0076$, log-rank test) and progression-free ($P = 0.0069$, log-rank test) survival time than patients with low SRC-3 levels. The mean overall survival time was 39.0 months for the SRC-3 overexpression group and 52.3 months for the SRC-3 normal expression group. By univariate analysis, overexpression of SRC-3 ($P = 0.006$), advanced tumor stage ($P < 0.0001$), presence of lymph node metastasis ($P < 0.0001$), and advanced clinical stage ($P < 0.0001$) were significant negative prognostic factors for OS in ESCC patients (Table 2). In the multivariate analysis, overexpression of SRC-3 ($P = 0.007$) and advanced tumor stage ($P = 0.017$) retained independent significant predictive value for survival enrolled in this study (Table 3).

Downregulation of SRC-3 inhibits ESCC cell proliferation
In order to evaluate the role of SRC-3 in ESCC cell function, two ESCC cell lines, Eca109 and EC18, expressed a
A moderate level of SRC-3 were selected to generated stable SRC-3 knockdown ESCC cell lines using shRNA transfection. Western blot experiment confirmed significant reduction in SRC-3 expression in SRC-3 knockdown cells relative to a scrambled control shRNA (Fig. 2A). As shown in Fig. 2B, the proliferation rate of endogenous SRC-3 knockdown Eca109 cells, as assessed by the BrdU assay, was significantly reduced to 44% compared to the scrambled control cells. A similar result was found in EC18 cells. In the MTT assay, relative cell viability of SRC-3 knockdown Eca109 and EC18 cells was significantly reduced to 55% and 52% by the seventh day, respectively (Fig. 2C).

To further characterize the effects of SRC-3 on tumor cell proliferation, a colony formation assay was performed.
As shown in Figure 2D and E, silencing SRC-3 significantly decreased the colony formation in both assays, demonstrating that SRC-3 enhances anchorage-independent growth and colony formation.

**Downregulation of SRC-3 arrests ESCC cell cycle at G1/S transition**

To elucidate the mechanism underlying growth inhibition by downregulation of SRC-3, flow cytometric analysis was performed to compare cell distributions in cell cycle between SRC-3 knockdown cells and control cells. The percentage of SRC-3 knockdown cells in G0/G1 phases was increased by 11% and 20% in Eca109 and EC18 cells, respectively; and this was associated with a concomitant decrease in cell in S phase compared with that in control cells, suggesting that SRC-3 knockdown was able to inhibit DNA synthesis and arrest cell cycle at G1/S transition (Fig. 3).

**SRC-3 enhances ESCC cell migration and invasion**

As the overexpression of SRC-3 examined by immunohistochemistry was positively associated with ESCC advanced tumor stage and ascending clinical stage, the effects of SRC-3 on ESCC cell migration and invasion were studied by wound healing and cell invasion assays, respectively. Wound healing assay showed that, 20 h after a wound was made on the monolayer of cells, the spreading speed of SRC-3 knockdown cells along the wound edge was slower than that in control cells, demonstrating that depletion of endogenous SRC-3 could dramatically inhibit cell migration ability in both Eca109 and EC18 cells (Fig. 4A). Matrigel invasion assay also found that knockdown of SRC-3 could inhibit the invasiveness of ESCC cells, as showed by a significant decrease in the number of invaded cells in Eca109 and EC18 cells compared to scramble control ($P < 0.001$, Fig. 4B). These results suggest that SRC-3 plays a critical role in migration and invasion of human ESCC cells.

**SRC-3 contributes to the progression of ESCC in vivo**

To further investigate the role of SRC-3 in ESCC progression, we assessed the effects of SRC-3 knockdown on the growth of ESCC xenograft tumors in nude mice injected with SRC-3 knockdown or control cells. SRC-3 knockdown Eca109 and EC18 tumors grew much slower than control tumors. At the end of the study (day 32),

### Table 2. Results of Univariate Cox Proportional Hazards Regression Analysis.

| Variable | No. of cases | $P$ | RR | 95% Confidence Interval for RR |
|----------|--------------|-----|----|-----------------------------|
| Age (<58 vs. >58) | 116/126 | 0.231 | 1.223 | 0.880-1.701 |
| Gender (Female vs. Male) | 58/184 | 0.741 | 1.065 | 0.732-1.550 |
| Differentiation (Well/Moderate vs. Poor) | 41/201 | 0.516 | 1.149 | 0.756-1.748 |
| SRC-3 (Overexpression vs. Normal) | 118/124 | 0.006 | 1.558 | 1.140-2.211 |
| T classification (T3-4 vs. T1-2) | 155/87 | 0.000 | 1.906 | 1.342-2.716 |
| N classification (N1-3 vs. N0) | 126/116 | 0.000 | 1.874 | 1.333-2.634 |
| M classification (M1 vs. M0) | 4/238 | 0.070 | 3.668 | 0.898-14.979 |
| Clinical stage (III-IV vs. I-II) | 105/137 | 0.000 | 2.013 | 1.442-2.809 |

**RR**, relative risk; **SRC**, Steroid receptor coactivator.

### Table 3. Results of Multivariate Cox Proportional Hazards Regression Analysis.

| Variable | No. of cases | $P$ | RR | 95% Confidence Interval for RR |
|----------|--------------|-----|----|-----------------------------|
| SRC-3 (Overexpression vs. Normal) | 118/124 | 0.007 | 1.582 | 1.134-2.207 |
| T classification (T3-4 vs. T1-2) | 155/87 | 0.017 | 1.657 | 1.092-2.512 |

**RR**, relative risk; **SRC**, Steroid receptor coactivator.
tumor size of SRC-3 knockdown group (309 ± 34 mm³, 293 ± 27 mm³) was only 43% and 48% of the control group (715 ± 51 mm³, 616 ± 27 mm³), respectively, and tumor weight of SRC-3-silenced group (229 ± 22 mg, 201 ± 14 mg) was also significantly lower than the scramble control group (537 ± 82 mg, 466 ± 61 mg), respectively (Fig. 5). These results indicate that SRC-3 contributes to the progression of ESCC cells in vivo.

**SRC-3 activates Insulin-like growth factor/AKT signaling pathway**

Downregulation of SRC-3 is frequently associated with inhibition of IGF/AKT signaling in several human cancers including breast cancer, prostate cancer, and HCC as well as ESCC [13, 16–18]. To test whether SRC-3-mediated ESCC pathogenesis was through IGF/AKT signaling pathway, mRNA and protein levels of numerous well-known genes of IGF/AKT signaling pathway were compared between control and SRC-3 knockdown cells by qPCR and Western blot analysis. As expected, parallel to the reduction in SRC-3, mRNA levels for IGF-I, IGF-II, IRS-1, IRS-2, PIK3CA, and AKT were all decreased (Fig. 6A). In both Eca109 and EC18 cells, protein level IGF-1, IGF-2, and IRS-1 were dramatically reduced; whereas PIK3CA had moderate reduction and IRS-2 and p-AKT only slight reduction in Eca109; PIK3CA and p-AKT dramatically reduced and IRS-2 slight reduction in EC18 (Fig. 6B). ChIP assay showed that SRC-3 was directly recruited onto the promoters of IGF-I, IGF-II, IRS-1, IRS-2, PIK3CA, and AKT (Fig. 6C), whereas no signals were detected in the negative control.
groups. Additional ChIP primers, primer sets 2, far from start sites of PIK3CA and AKT1 did not detect SRC-3 binding activity which further demonstrate that the associations was site specific. These results indicated that these genes were direct transcriptional targets of SRC-3. Overall, these data demonstrated that SRC-3 indeed regulated the expression of many components of the IGF/AKT pathway in ESCC cell lines.

Discussion

Previously, our study have showed that SRC-3 was frequently amplified and overexpressed in ESCC, and the overexpression of SRC-3 was closely associated with increased cell proliferation and advanced tumor stage [15]. However, the role and molecular mechanism by which SRC-3 regulates ESCC cell aggressiveness remain unclear. In this study, the results of another larger cohort of ESCCs analyzed by IHC validated our previous findings that SRC-3 was frequently overexpressed in ESCC tissues and it was significantly correlated with advanced tumor stage and seemed to be more common with advanced clinical stage, suggesting that the upregulated expression of SRC-3 in ESCC may facilitate the invasive phenotype.

Importantly, we further found that patients whose tumor showed SRC-3 overexpression had inferior survival compared to those with SRC-3 normal expression, and the overexpression of SRC-3 was also an independent prognostic predictor in multivariate analysis. This finding in the large-scale analysis for ESCC patients after curative resection (operable ESCC) is in agreement with previous reports on a small number of patient cases (n = 98) with locally advanced disease treated with definite chemoradiotherapy [19]. Therefore, SRC-3 expression could thus be an additional predictive marker for tumor progression for ESCC patients. These findings underscore a potentially important role of SRC-3 as an underlying biological mechanism in the tumorigenic process of ESCC.

Multiple studies have demonstrated that overexpression of SRC-3 provides a growth advantage for tumor cells and promotes tumor development through several ways independent of nuclear receptor signaling in various human cancers [6, 13, 14, 20, 21]. Cardiac glycoside bufalin, a
potent small molecule inhibitor for SRC-3, has been reported to strongly promote SRC-3 protein degradation and was able to block cancer cell growth at nanomolar concentrations [22]. When incorporated into a nanoparticle delivery system, bufalin was able to reduce tumor growth in a mouse xenograft model of breast cancer. This notion was supported by our findings that shRNA-mediated SRC-3 knockdown causes inhibition of cell growth and colony formation in vitro and the in vivo growth inhibition of tumors in nude mice of two different ESCC cell lines.

Malignant tumor cell proliferation is one of the predominant characteristics in cancer development and cell cycle progression is critical for cell proliferation [23]. SRC-3 has been demonstrated to control prostate cancer
and other epithelial cancers cell proliferation and tumor growth through modulating cell cycle [8, 13, 24]. We observed that reduction in SRC-3 expression by shRNA in Eca109 and EC18 cells decreased BrdU incorporation and delayed the G1-S transition. These results suggest that this proliferative effect of SRC-3 on ESCC cells via promoting DNA synthesis resulting in cell cycle progression from G1 to S phase. Given that SRC-3 is known to coactivate other transcription factors such as E2F1, AP-1, Ets-2, and PEA3 to regulate the expression of cell cycle genes, and these transcription factors have been implicated in ESCC, further work is needed to investigate the potential link between these transcription factors and SRC-3 and their possible role in the pathogenesis and progression of ESCC [18, 25–31].

Invasion plays a critical role in cancer progression and is one of the major poor prognostic factors in patients with ESCC. The ability of SRC-3 promoting cell migration and invasion has been demonstrated in several studies using animal or cell culture models [26, 32, 33]. Consistent with these findings, we showed that shRNA-mediated SRC-3 knockdown in the Eca109 and EC18 cells inhibited the ability of either cell migration or invasion. Our data indicated that SRC-3 exerted a vital role to facilitate ESCC cells aggressive phenotype. A limitation of this study should be addressed is that the effect of SRC-3 on invasion in vivo, in particular on metastasis was not demonstrated. An orthotopic model of human ESCC in nude mouse, simulated human body environment, would better illustrate effect of SRC-3 on growth and metastasis of tumor in vivo. However, it is really difficult to achieve.

The mechanism of SRC-3 regulating cancer migration and invasion has been focused on SRC-3 regulating the expression of matrix metalloproteinases (MMPs) and/or activating focal adhesion kinase (FAK) signaling in previous studies [6, 26, 32–34]. Many studies reported that MMPs and FAK signaling participated in the development of ESCC and resulted in poor prognosis [35–37]. Thus, integrating these studies and our results, it is reasonable to speculate that SRC-3 may also function through upregulating MMPs expression and activating FAK signaling to enhance human esophageal cancer cell migration and invasion. However, the interaction between SRC-3 and MMPs and FAK signaling in ESCC need to be further investigated.

IGF/AKT signaling pathway is involved in many important cell processes related to cancer [38, 39]. Deregluation of multiple IGF/AKT signaling components have been detected in a wide variety of human carcinomas and considered to play a central role in cancer progression [16–18, 40, 41]. Human esophageal epithelial cells express IGF-IR,
and IGF-I is known to stimulate both thymidine incorporation and proliferation in these cells [42]. Adachi et al. reported that inhibition of IGF-IR suppressed proliferation, colony formation, and motility through blocking ligand-induced AKT activation [43]. These studies demonstrate that IGF/AKT signaling also play a key role in ESCC cells aggressiveness [42–44]. Accumulated evidences show that SRC-3 is associated with the regulation of IGF/AKT pathway in several types of cancers. In agreement with these findings, we found that depletion of SRC-3 also caused a decreased expression of IGF/AKT signaling components both in mRNA and protein level in ESCC cell lines. Moreover, ChIP assay showed that the regulation of these genes by SRC-3 was at the transcription level and it occurred via direct recruitment of SRC-3 to the promoters of those genes. In addition, we found that overexpression of SRC-3 in HEEC not only promoted its growth rates but also enhanced IGF/AKT downstream target genes expression (Fig. 7). Also, the level of SRC-3 was correlated with p-AKT expression in our ESCC specimens (data not shown). These suggested that activation of IGF/AKT was also involved in the effect of SRC-3 on the ESCC cell growth and invasiveness. SRC-3 has been shown to promote HCC cell proliferation through activation of the AKT signaling pathway to regulate cycle control-related gene such as inhibit cell cycle inhibitor p21Cip1/Waf1 expression, whereas PI3K/AKT inhibitor LY294002 can abolish the effect of SRC-3 [13]. The role of SRC-3 enhancing HCC cell invasiveness was also demonstrated via PI3K/AKT pathways to upregulating MMP-9 expression both in vitro and in vivo. Together with these studies, our results support the previous findings that SRC-3 activating many important components of IGF/AKT pathway at both transcription and phosphorylation levels should lead to tumor progression by ensuring the efficient downstream signaling to enhance growth and invasion [16, 18]. However, SRC-3 is likely to be involved in multiple signaling pathways during the development of cancer. They are considered as master regulators of differential gene expression and accomplish this through combinatorial codes of posttranslational modifications, which involve mainly phosphorylation, ubiquitination, and sumoylation [22, 27, 45]. Future studies are necessary to elucidate detailed mechanisms that affect esophageal cancer behavior.

In summary, our studies illustrate that SRC-3 overexpression is clinically and functionally relevant to the progression of human ESCC. Understanding the precise role of SRC-3 in the pathogenesis of ESCC and activation of the IGF/AKT pathway will increase our knowledge of the biologic basis of cancer progression and disruption of functions of SRC-3 or its target genes and pathways may have potential therapeutic advantages for ESCC.

**Figure 7.** Overexpression of Steroid receptor coactivator (SRC)-3 promotes human normal esophageal epithelial cell proliferation and activating insulin-like growth factor (IGF)/AKT signaling pathway. (A) Overexpression of SRC-3 in immortalized human normal esophageal epithelial cell (HEEC) by immunoblotting. β-actin was used as a loading control. (B) Overexpression of SRC-3 promotes growth rate of HEEC as determined by MTT assay. (C) Western blotting analysis of expression of IGF/AKT components, including IGF-I, IGF-II, IRS-1, IRS-2, PIK3CA, AKT, and p-AKT from indicated cells. β-actin was used as a loading control. MTT, Methyl thiazolyl tetrazolium. *P < 0.05 and **P < 0.01.
SRC-3 Promotes ESCC Aggressiveness

Acknowledgments
We thank Prof. Jian-Ming Wen and Dan Xie for helpful discussions, and Drs. Wei-Xia Zeng for technical assistance.

Conflicts of Interest
No potential conflicts of interest were disclosed.

References
1. Ferlay, J., H. R. Shin, F. Bray, D. Forman, C. Mathers, and D. M. Parkin. 2010. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917.
2. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J Clin. 61:69–90.
3. Gertler, R., H. J. Stein, R. Langer, M. Nettelmann, T. Schuster, and H. Hoefler. 2011. Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 253:689–698.
4. Allum, W. H., S. P. Stenning, J. Bancewicz, P. I. Clark, and R. E. Langley. 2009. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 27:5062–5067.
5. Yan, J., S. Y. Tsai, and M. J. Tsai. 2006. SRC-3/AIB1: transcriptional coactivator in oncogenesis. Acta Pharmacol Sin. 27:387–394.
6. Ma, G., Y. Ren, K. Wang, and J. He. 2011. SRC-3 has a role in cancer other than as a nuclear receptor coactivator. Int J Biol Sci. 7:664–672.
7. Dihe, L., P. O. Bendahl, D. Grabau, J. Isola, K. Lövgren, and L. Rydén. 2008. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat. 109:255–262.
8. Zhou, H. J., J. Yan, W. Luo, G. Ayala, S. H. Lin, and H. Erdem. 2005. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65:7976–7983.
9. Sakakura, C., A. Hagiwara, R. Yasuoka, Y. Fujita, M. Nakanishi, and K. Masuda. 2000. Amplification and over-expression of the AIB1 nuclear receptor coactivator gene in primary gastric cancers. Int J Cancer 89:217–223.
10. Henke, R. T., B. R. Haddad, S. E. Kim, J. D. Rone, A. Mani, and J. M. Jessup. 2004. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. Clin Cancer Res. 10:6134–6142.
11. Luo, J. H., D. Xie, M. Z. Liu, W. Chen, Y. D. Liu, and G. Q. Wu. 2008. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival. Int J Cancer 122:2554–2561.
12. Wang, Y., M. C. Wu, J. S. Sham, W. Zhang, W. Q. Wu, and X. Y. Guan. 2002. Prognostic significance of c-myc and AIB1 amplification in hepatocellular carcinoma. A broad survey using high-throughput tissue microarray. Cancer 95:2346–2352.
13. Xu, Y., Q. Chen, W. Li, X. Su, T. Chen, and Y. Liu. 2010. Overexpression of transcriptional coactivator AIB1 promotes hepatocellular carcinoma progression by enhancing cell proliferation and invasiveness. Oncogene 29:3386–3397.
14. Cai, D., D. S. Shames, M. G. Raso, Y. Xie, Y. H. Kim, and J. R. Pollack. 2010. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 70:6477–6485.
15. Xu, F. P., D. Xie, J. M. Wen, H. X. Wu, Y. D. Liu, and J. Bi. 2007. SRC-3/AIB1 protein and gene amplification levels in human esophageal squamous cell carcinomas. Cancer Lett. 245:69–74.
16. Oh, A., H. J. List, R. Reiter, A. Mani, Y. Zhang, and E. Gehan. 2004. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Res. 64:8299–8308.
17. Torres-Arroyos, M. L., J. Font de Mora, J. Yuan, F. Vazquez, R. Bronson, and M. Rue. 2004. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6:263–274.
18. Yan, J., C. T. Yu, M. Ozen, M. Ittmann, S. Y. Tsai, and M. J. Tsai. 2006. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Res. 66:11039–11046.
19. He, L. R., M. Z. Liu, B. K. Li, H. L. Rao, H. X. Deng, and X. Y. Guan. 2009. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 100:1591–1596.
20. Gojis, O., B. Rudraraju, C. Alifrangis, J. Krell, P. Libalova, and C. Palmieri. 2010. The role of steroid receptor coactivator-3 (SRC-3) in human malignant disease. Eur J Surg Oncol. 36:224–229.
21. Ying, H., M. C. Willingham, and S. Y. Cheng. 2008. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer. Oncogene 27:823–830.
SRC-3 Promotes ESCC Aggressiveness

F.-P. Xu et al.

22. Wang, Y., D. M. Lonard, Y. Yu, D. C. Chow, T. G. Palzkill, and J. Wang. 2014. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 7:1506–1517.

23. Park, M. T., and S. J. Lee. 2003. Cell cycle and cancer. J. Biochem. Mol. Biol. 36:650–656.

24. Louie, M. C., A. S. Revenko, J. X. Zou, J. Yao, and H. W. Chen. 2006. Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Mol. Cell. Biol. 26:3810–3823.

25. Louie, M. C., J. X. Zou, A. Rabinovich, and H. W. Chen. 2004. ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell. Biol. 24:5157–5171.

26. Qin, L., L. Liao, A. Redmond, L. Young, Y. Yuan, and H. Chen. 2008. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol. Cell. Biol. 28:5937–5950.

27. Tien, J. C., and J. Xu. 2012. Steroid receptor coactivator-3 as a potential molecular target for cancer therapy. Expert. Opin. Ther. Targets. 16:1085–1096.

28. Mega, S., M. Miyamoto, Y. Ebihara, R. Takahashi, R. Hase, and L. Li. 2005. Cyclin D1, E2F1 expression levels are associated with characteristics and prognosis of esophageal squamous cell carcinoma. Dis. Esophagus 18:109–113.

29. Hussain, S., A. C. Bharti, I. Salam, M. A. Bhat, M. M. Mir, and S. Hedau. 2009. Transcriptor factor AP-1 in esophageal squamous cell carcinoma: alterations in activity and expression during human Papilloma virus infection. BMC Cancer 9:329.

30. Li, X., J. Y. Lu, L. Q. Zhao, X. Q. Wang, G. L. Liu, and Z. Liu. 2003. Overexpression of ETS2 in human esophageal squamous cell carcinoma. World J. Gastroenterol. 9:205–208.

31. Yuen, H. F., C. M. McCrudden, Y. P. Chan, M. L. Wong, and K. Y. Chan. 2011. The role of PEA3 group transcription factors in esophageal squamous cell carcinoma. Am. J. Pathol. 179:992–1003.

32. Yan, J., H. Erdem, R. Li, Y. Cai, G. Ayala, and M. Ittmann. 2008. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 68:5460–5468.

33. Li, L. B., M. C. Louie, H. W. Chen, and J. X. Zou. 2008. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett. 261:64–73.

34. Long, W., C. E. Foulds, J. Qin, J. Liu, C. Ding, and D. M. Lonard. 2012. ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J. Clin. Invest. 122:1869–1880.

35. Gu, Z. D., J. Y. Li, M. Li, X. T. Shi, Y. Ke, and K. N. Chen. 2005. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am. J. Gastroenterol. 100:1835–1843.

36. Li, Y., J. Ma, Q. Guo, F. Duan, F. Tang, and P. Zheng. 2009. Overexpression of MMP-2 and MMP-9 in esophageal squamous cell carcinoma. Dis. Esophagus 22:664–667.

37. Miyazaki, T., H. Kato, M. Nakajima, M. Sohda, Y. Fukai, and N. Masuda. 2003. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br. J. Cancer 89:140–145.

38. Pollak, M. N., E. S. Schernhammer, and S. E. Hankinson. 2004. Insulin-like growth factors and neoplasia. Nat. Rev. Cancer 4:505–518.

39. Bader, A. G., S. Kang, L. Zhao, and P. K. Vogt. 2005. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5:921–929.

40. Larsson, O., A. Girnita, and L. Girnita. 2005. Role of insulin-like growth factor 1 receptor signalling in cancer. Br. J. Cancer 92:2097–2101.

41. Liao, L., X. Chen, S. Wang, A. F. Parlow, and J. Xu. 2008. Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-1) by controlling IGF-binding protein 3 expression. Mol. Cell. Biol. 28:2460–2469.

42. Imamura, A., Y. Adachi, H. Yamamoto, R. Li, Y. Wang, and Y. Min. 2007. Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28:947–956.

43. Adachi, Y., H. Ohashi, A. Imamura, H. Yamamoto, Y. Matsunaga, and H. Taniguchi. 2014. The effect of IGF-I receptor blockade for human esophageal squamous cell carcinoma and adenocarcinoma. Tumour Biol. 35:973–985.

44. Li, B., S. W. Tsao, Y. Y. Li, X. Wang, M. T. Ling, and Y. C. Wong. 2009. Id-1 promotes tumorigenicity and metastasis of human esophageal cancer cells through activation of PI3K/AKT signaling pathway. Int. J. Cancer 125:2576–2585.

45. York, B., and B. W. O’Malley. 2012. Steroid receptor coactivator (SRC) family: masters of systems biology. Biol. Chem. 285:38743–38750.

Supporting Information

Additional supporting information may be found in the online version of this article:

Appendix S1. Supplementary Materials and Methods.